Analysts coverage around the corner We're getting closer and closer to analysts coverage
Normal part of the process, considering p#5 and p#6 12-month data, all that's coming in June and taking into consideration upcoming Ph. 2b 3-month interim data around October from the first UHN cohort.
May 30, 2019 University Health Hospital ("UHN") is the first site to obtain REB approval and commence Study II and is currently screening patients for enrollment in Study II.
The Company is currently working with 3 additional institutional clinical oncology sites, already in the final negotiation phases with the Company, for commencing Study II in their respective organization in 3Q 2019.
Theralase has confirmed a conference call with the Food and Drug Administration ("FDA") to discuss the design and endpoints of Study II, via a Pre-Investigational New Drug ("PIND") meeting in late June 2019. Pending completion of this conference call, the Company plans to submit an Investigational New Drug ("IND") application to the FDA and subject to their final review and approval, the Company will commence on-boarding institutional clinical oncology sites in the United States for Study II.
Not to mention the following ...
_________________
Claridge - (5/31/2019 2:57:25 PM) June will bring lots of interesting advances/visibility
- 3 presentations (1 with 9 papers)
- 1 conference (CUA)
- FDA conference call
- 3 canadian sites in final discussion to join Ph. 2b
- AGM